European Journal of Pharmacology, 138 (1987) 451–456
Elsevier

AUTHOR INDEX

Agostini, R., see Manzini, S. (138) 375
Alkadhi, K.A.
Effects of emetine and dehydroemetine at the frog neuromuscular junction (138) 257
Appel, J.B., see Cunningham, K.A. (138) 29

Bacciarelli, C., see Manzini, S. (138) 307
Ballati, L., see Manzini, S. (138) 375
Baraban, J.M., see Heller, W.A. (138) 115
Barchas, J.D., see Hurlbut, D.E. (138) 359
Barnett, C.J.K., see O'Donnell, S.R. (138) 385
Barone, P., Tucci, I., Parashos, S.A. and Chase, T.N.
D-1 dopamine receptor changes after striatal quinolinic acid lesion (138) 141
Bast, A., see Van der Werf, J.F. (138) 199
Batra, S.
Comparison of muscarinic acetylcholine binding in the urinary bladder and submandibular gland of the rabbit (138) 83
Bennett, A., see Capasso, F. (138) 107
Bernstein, P.R., see Snyder, D.W. (138) 397
Bertrand, P., see Chneiweiss, H. (138) 249
Bigby, T.D., see Tamaoki, J. (138) 421
Bijloo, G.J., see Van der Werf, J.F. (138) 199
Biziere, K., see Worms, P. (138) 343
Bobker, D.H., see Campbell, B.G. (138) 447
Bouveret, P., see Nokin, P. (138) 277
Braquet, P., see Egido, J. (138) 119
Broch, O.J., see Hunskaar, S. (138) 77
Brouillet, E., see Hantraye, P. (138) 239
Bucher, B. and Stoclet, J.-C.
Adrenomedullary and β-adrenergic participation in enhanced sympathetic pressor responses of spontaneously hypertensive rats (138) 233
Burnstock, G., see Kirkpatrick, K. (138) 207
Burnstock, G., see Reilly, W.M. (138) 319
Butler, A., see Hagan, R.M. (138) 303

Callahan, P.M., see Cunningham, K.A. (138) 29
Campbell, B.G., Bobker, D.H., Leslie, F.M., Mefford, I.N. and Weber, E.
Both the σ receptor-specific ligand (+)3-PPP and the PCP receptor-specific ligand TCP act in the mouse vas deferens via augmentation of electrically evoked norepinephrine release (138) 447
Candy, J.M., see Whitford, C.A. (138) 327
Capasso, F., Tavares, I.A., Tsang, R., Rennie, J.A. and Bennett, A.
Eicosanoid formation by mammalian intestine. Effects of some intestinal secretagogues (138) 107
Capdevila, J., see Carroll, M.A. (138) 281
Carroll, M.A., Schwartzman, M., Capdevila, J., Falck, J.R. and McGiff, J.C.
Vasoactivity of arachidonic acid epoxides (138) 281
Carruba, M.O., see Memo, M. (138) 45
Chambon, J.-P., see Worms, P. (138) 343
Chase, T.N., see Barone, P. (138) 141
Chavoix, C., see Hantraye, P. (138) 239
Chneiweiss, H., Bertrand, P., Epelbaum, J., Kordon, C., Glowinski, J., Premont, J. and Enjalbert, A.
Somatostatin receptors on cortical neurones and adenohypophysis: comparison between specific binding and adenylate cyclase inhibition (138) 249
Choi, D.W., see Kim, J.P. (138) 133
Cognard, C., see Raymond, G. (138) 21
Conti, S., see Manzini, S. (138) 375
Crespo, M.S., see Egido, J. (138) 119
Crouzel, M., see Hantraye, P. (138) 239
Cunningham, K.A., Callahan, P.M. and Appel, J.B.
Discriminative stimulus properties of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OHDPAT): implications for understanding the actions of novel anxiolytics [1] (138) 29
Curzon, G., see Hutson, P.H. (138) 215
Curzon, G., see Kennett, G.A. (138) 53
Czyrak, A., see Mogilnicka, E. (138) 413

Daly, R.N. and Hieble, J.P.
Neuropeptide Y modulates adrenergic neurotransmission by an endothelium dependent mechanism (138) 445
Dashwood, M.R., see Sullivan, A.F. (138) 169
Dawson, T.M., see Filloux, F.M. (138) 61
Decker, N., see Grima, M. (138) 1
Den Hertog, A. and Van den Akker, J.
Modification of α_1-receptor-operated channels by mebeverine in smooth muscle cells of guinea-pig taenia caeci (138) 367
Dickenson, A.H., see Sullivan, A.F. (138) 169
Dion, S., Drapeau, G., Rhaleb, N.-E., D'Orléans-Juste, P. and Regoli, D.
Receptors for substance P and neurokinins. Correlation between binding and biological activities (138) 125
Dodd, R.H., see Hantraye, P. (138) 239
Donohoe, T.P., see Hutson, P.H. (138) 215
D'Orléans-Juste, P., see Dion, S. (138) 125
Dourish, C.T., see Kennett, G.A. (138) 53
Drapeau, G., see Dion, S. (138) 125

Egido, J., Robles, A., Ortiz, A., Ramirez, F., Gonzalez, E., Mampaso, F., Crespo, M.S., Braquet, P. and Hernando, L.
Role of platelet-activating factor in adriamycin-induced nephropathy in rats (138) 119
Ekelund, M., Håkanson, R. and Vallgren, S.
Effects of cimetidine, atropine and pirenzepine on basal and stimulated gastric acid secretion in the rat (138) 225
Emmett-Oglesby, M.W., see Wood, D.M. (138) 155
Enjalbert, A., see Chneiweiss, H. (138) 249
Epelbaum, J., see Chneiweiss, H. (138) 249
Evans, C.J., see Hurlbut, D.E. (138) 359

Falck, J.R., see Carroll, M.A. (138) 281
Fasmer, O.B., see Hunskaar, S. (138) 77
Fastbom, J., see Palacios, J.M. (138) 273
Filloux, F.M., Wamsley, J.K. and Dawson, T.M.
Dopamine D-2 auto- and postsynaptic receptors in the nigrostriatal system of the rat brain: localization by quantitative autoradiography with [^{3}H]sulpiride (138) 61
Finberg, J.P.M. and Kopin, I.J.
Chronic clonidine treatment produces desensitisation of post- but not presynaptic α_2-adrenoceptors (138) 95
Fletcher, G.H. and Starr, M.S.
Behavioural evidence for the functionality of D-2 but not D-1 dopamine receptors at multiple brain sites in the 6-hydroxydopamine-lesioned rat (138) 407
Fozard, J.R., see Ramage, A.G. (138) 179
Freissmuth, M., Nanoff, C., Tuisl, E. and Schuetz, W.
Stimulation of adenylate cyclase activity via A_2-adenosine receptors in isolated tubules of the rabbit renal cortex (138) 137
Freyss-Beguin, M., see Grima, M. (138) 1
Fukuda, H., see Hantraye, P. (138) 239
Fukushima, N., see Ueda, H. (138) 129
Furukawa, T., see Kawasaki, H. (138) 351

Gagnol, J.-P., see Nokin, P. (138) 277
Gallo, V., Suergiu, R. and Levi, G.
Functional evaluation of glutamate receptor subtypes in cultured cerebellar neurones and astrocytes (138) 293
Gavish, M., see Weizman, R. (138) 289
Geppetti, P., see Manzini, S. (138) 307
Gibb, J.W., see Merchant, K.M. (138) 151
Glowinski, J., see Chneiweiss, H. (138) 249
Goldberg, M.P., see Kim, J.P. (138) 133
Golomb, M., see Weizman, R. (138) 289
Gonzalez, E., see Egido, J. (138) 119
Graf, P.D., see Tamaoki, J. (138) 421
Granek, M., see Weizman, R. (138) 289
Grenie, B., see Roquebert, J. (138) 433
Grima, M., Freyss-Beguin, M., Millanvoye-Van Brussel, E., Decker, N. and Schwartz, J.
Effects of various antianginal drugs on sodium influx in rat brain synaptosomes and in rat heart muscle cells in culture (138) 1
Guibert, B., see Hantraye, P. (138) 239

Hagan, R.M., Butler, A., Hill, J.M., Jordan, C.C., Ireland, S.J. and Tyers, M.B.
Effect of the 5-HT_3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain (138) 303
Håkanson, R., see Ekelund, M. (138) 225
Halsey, M.J., see Wardley-Smith, B. (138) 417
Hanson, G.R., see Merchant, K.M. (138) 151
Hantraye, P., Chavoix, C., Guibert, B., Fukuda, H., Brouillet, E., Dodd, R.H., Prenant, C., Crouzel, M., Naquet, R. and Mazière, M.
Benzodiazepine receptors studied in living primates by positron emission tomography: inverse agonist interactions (138) 239
Hara, T., see Ushijima, I. (138) 101
Heinle, H., see Lindner, V. (138) 147
Heller, W.A. and Baraban, J.M.
Potent agonist activity of DOB at 5-HT_2 receptors in guinea pig trachea (138) 115
Herdon, H., Strupish, J. and Nahorski, S.R.
Endogenous dopamine release from rat striatal slices and its regulation by D-2 autoreceptors: effects of uptake inhibitors and synthesis inhibition (138) 69
Hernando, L., see Egido, J. (138) 119
Hieble, J.P., see Daly, R.N. (138) 445
Hill, J.M., see Hagan, R.M. (138) 303
Hirst, B.H., see Whitford, C.A. (138) 327
Hole, K., see Hunskaar, S. (138) 77
Hrdina, P.D.
Regulation of high- and low-affinity [^{3}H]imipramine recognition sites in rat brain by chronic treatment with antidepressants (138) 159
Hunskaar, S., Fasmer, O.B., Broch, O.J. and Hole, K.
Involvement of central serotonergic pathways in nefopam-induced antinociception (138) 77
Hurlbut, D.E., Evans, C.J., Barchas, J.D. and Leslie, F.M.
Pharmacological properties of a proenkephalin A-derived opioid peptide: BAM 18 (138) 359
Hutson, P.H., Donohoe, T.P. and Curzon, G.
Neurochemical and behavioural evidence for an agonist action of 1-[2-(4-aminophenyl)ethyl]-4-(3-trifluoromethylphenyl)piperazine (LY 165163) at central 5-HT receptors (138) 215

Introini-Collison, I.B., see Zhang, S.-y. (138) 37
Ireland, S.J., see Hagan, R.M. (138) 303

Jacquet, Y.F., Saederup, E. and Squires, R.F.
Non-stereospecific excitatory actions of morphine may be due to GABA-A receptor blockade (138) 285
Jahn, W., see Raymond, G. (138) 21
Johnson, M., see Merchant, K.M. (138) 151
Johnson, M., see Whitford, C.A. (138) 327
Jordan, C.C., see Hagan, R.M. (138) 303
Juler, R.G., see Zhang, S.-y. (138) 37
Jungbluth, L., see Nokin, P. (138) 277

Karp, L., see Weizman, R. (138) 289
Kawasaki, H., Takasaki, K. and Furukawa, T.
Exaggerated pressor response to centrally administered renin in freely moving, spontaneously hypertensive rats (138) 351
Keen, P., see Nielsch, U. (138) 193
Kennett, G.A., Marcou, M., Dourish, C.T. and Curzon, G.
Single administration of 5-HT_{1A} agonists decreases 5-HT_{1A} presynaptic, but not postsynaptic receptor-mediated responses: relationship to antidepressant-like action (138) 53
Kigoshi, S., see Muramatsu, I. (138) 269
Kim, J.P., Goldberg, M.P. and Choi, D.W.
High concentrations of naloxone attenuate N-methyl-D-aspartate receptor-mediated neurotoxicity (138) 133
Kirkpatrick, K. and Burnstock, G.
Sympathetic nerve-mediated release of ATP from the guinea-pig vas deferens is unaffected by reserpine (138) 207
Kishimoto, O., see Ushijima, I. (138) 101
Kopin, I.J., see Finberg, J.P.M. (138) 95
Kordon, C., see Chneiweiss, H. (138) 249

Leslie, F.M., see Campbell, B.G. (138) 447
Leslie, F.M., see Hurlbut, D.E. (138) 359
Letter, A.A., see Merchant, K.M. (138) 151
Levi, G., see Gallo, V. (138) 293
Lindner, V. and Heinle, H.
Ca^{2+} influx in spontaneously hypertensive rats is sensitive to calcium antagonists (138) 147

Maggi, C.A., see Manzini, S. (138) 307
Maiorano, L., see Watts, J. (138) 335
Maj, J., see Mogilnicka, E. (138) 413
Mampaso, F., see Egido, J. (138) 119
Manzini, S., Conti, S., Agostini, R. and Ballati, L.
Blockade by theophylline of capsaicin-induced motor effects in guinea-pig airways (138) 375
Manzini, S., Maggi, C.A., Geppetti, P. and Bacciarelli, C.
Capsaicin desensitization protects from antigen-induced bronchospasm in conscious guinea-pigs (138) 307
Marcou, M., see Kennett, G.A. (138) 53
Mazière, M., see Hantraye, P. (138) 239
McGaugh, J.L., see Zhang, S.-y. (138) 37
McGiff, J.C., see Carroll, M.A. (138) 281
Mefford, I.N., see Campbell, B.G. (138) 447
Meldrum, B.S., see Wardley-Smith, B. (138) 417
Memo, M., Pizzi, M., Nisoli, E., Missale, C., Carruba, M.O. and Spano, P.
Repeated administration of (−)sulpiride and SCH 23390 differentially up-regulate D-1 and D-2 dopamine receptor function in rat mesostriatal areas but not in cortical-limbic brain regions (138) 45
Mercadier, J.-J., see Nokin, P. (138) 277
Merchant, K.M., Letter, A.A., Johnson, M., Stone, D.M., Gibb, J.W. and Hanson, G.R.
Effects of amphetamine analogs on neurotensin concentrations in rat brain (138) 151
Millanvoye-Van Brussel, E., see Grima, M. (138) 1
Misawa, H., see Ueda, H. (138) 129
Missale, C., see Memo, M. (138) 45
Mizuki, Y., see Ushijima, I. (138) 101
Mogilnicka, E., Czyrak, A. and Maj, J.
Dihydropyridine calcium channel antagonists reduce immobility in the mouse behavioral despair test; antidepressants facilitate nifedipine action (138) 413
Mokler, D.J., Robinson, S.E. and Rosecrans, J.A.
(±)3,4-Methylenedioxymethamphetamine (MDMA) produces long-term reductions in brain 5-hydroxytryptamine in rats (138) 265
Moraru, I.I., Popescu, L.M., Vidulescu, C. and Tzigaret, C.
Antibodies against phospholipase C inhibit smooth muscle contraction induced by acetylcholine and histamine (138) 427
Muramatsu, I., Noda, M., Nishio, M. and Kigoshi, S.
Histamine increases the Ca current in guinea-pig ventricular myocytes (138) 269
Musacchio, J.M., see Sharma, P.M. (138) 9

Nadel, J.A., see Tamaoki, J. (138) 421
Nahorski, S.R., see Herdon, H. (138) 69
Nahum, D., see Nokin, P. (138) 277
Nanoff, C., see Freissmuth, M. (138) 137
Naquet, R., see Hantraye, P. (138) 239
Nielsch, U. and Keen, P.
Effects of neonatal 6-hydroxydopamine administration on different substance P-containing sensory neurones (138) 193
Nishio, M., see Muramatsu, I. (138) 269
Nisoli, E., see Memo, M. (138) 45
Noda, M., see Muramatsu, I. (138) 269
Nokin, P., Mercadier, J.-J., Nahum, D., Bouveret, P., Wisnewsky, C., Jungbluth, L., Gagnol, J.-P. and Schwartz, K.
Effect of amiodarone on myosin isoenzymic distribution in rat ventricular myocardium (138) 277

Oakley, A.E., see Whitford, C.A. (138) 327
O'Donnell, S.R. and Barnett, C.J.K.
Microvascular leakage to platelet activating factor in guinea-pig trachea and bronchi (138) 385
Ortiz, A., see Egido, J. (138) 119

Palacios, J.M., Fastbom, J., Wiederhold, K.-H. and Probst, A.
Visualization of adenosine A_1 receptors in the human and the guinea-pig kidney (138) 273
Parashos, S.A., see Barone, P. (138) 141
Peroutka, S.J., see Wang, S.S. (138) 439
Pizzi, M., see Memo, M. (138) 45
Popescu, L.M., see Moraru, I.I. (138) 427
Potreau, D., see Raymond, G. (138) 21
Premont, J., see Chneiweiss, H. (138) 249
Prenant, C., see Hantraye, P. (138) 239
Probst, A., see Palacios, J.M. (138) 273

Ramage, A.G. and Fozard, J.R.
Evidence that the putative 5-HT_{1A} receptor agonists, 8-

OH-DPAT and ipsapirone, have a central hypotensive action that differs from that of clonidine in anaesthetised cats (138) 179
Ramirez, F., see Egido, J. (138) 119
Raymond, G., Potreau, D., Cognard, C., Jahn, W. and Wieland, T.
Antamanide antagonizes the phalloidin-induced negative inotropic effect and blocks voltage dependently the fast outward K^+ current in voltage-clamped frog muscle fibres (138) 21
Regoli, D., see Dion, S. (138) 125
Reilly, W.M. and Burnstock, G.
The effect of ATP analogues on the spontaneous electrical and mechanical activity of rat portal vein longitudinal muscle (138) 319
Rennie, J.A., see Capasso, F. (138) 107
Rhaleb, N.-E., see Dion, S. (138) 125
Ricaurte, G.A., see Wang, S.S. (138) 439
Robinson, S.E., see Mokler, D.J. (138) 265
Robles, A., see Egido, J. (138) 119
Roquebert, J. and Grenie, B.
Presynaptic inhibition by dihydroergotoxine of the response to peripheral sympathetic nerve stimulation in rats (138) 433
Rosecrans, J.A., see Mokler, D.J. (138) 265

Saederup, E., see Jacquet, Y.F. (138) 285
Samanin, R., see Wu, H.-Q. (138) 309
Schauf, C.L.
Bepridil and valproate retard Na^+ reactivation in *Myxicola* (138) 89
Schuetz, W., see Freissmuth, M. (138) 137
Schwartz, J., see Grima, M. (138) 1
Schwartz, K., see Nokin, P. (138) 277
Schwartzman, M., see Carroll, M.A. (138) 281
Sekizawa, K., see Tamaoki, J. (138) 421
Sharma, P.M. and Musacchio, J.M.
N-ethylmaleimide blocks the modulatory effects of divalent cations and guanine nucleotides on the brain substance P receptor (138) 9
Snell, C.R., see Whitford, C.A. (138) 327
Snyder, D.W. and Bernstein, P.R.
Pharmacologic profile of chemically stable analogs of peptide leukotrienes (138) 397
Soeda, K., see Ushijima, I. (138) 101
Spano, P., see Memo, M. (138) 45
Squires, R.F., see Jacquet, Y.F. (138) 285
Starr, M.S., see Fletcher, G.H. (138) 407
Stevens, C.W., Weinger, M.B. and Yaksh, T.L.
Intrathecal dynorphins suppress hindlimb electromyographic activity in rats (138) 299
Stoclet, J.-C., see Bucher, B. (138) 233
Stone, D.M., see Merchant, K.M. (138) 151
Strupish, J., see Herdon, H. (138) 69
Suergiu, R., see Gallo, V. (138) 293
Sullivan, A.F., Dashwood, M.R. and Dickenson, A.H.
α_2-Adrenoceptor modulation of nociception in rat spinal cord: location, effects and interactions with morphine (138) 169

Takagi, H., see Ueda, H. (138) 129
Takasaki, K., see Kawasaki, H. (138) 351
Tamaoki, J., Sekizawa, K., Ueki, I.F., Graf, P.D., Nadel, J.A. and Bigby, T.D.
Effect of macrophage stimulation on parasympathetic airway contraction in dogs (138) 421
Tanne, Z., see Weizman, R. (138) 289
Tavares, I.A., see Capasso, F. (138) 107
Thompson, J.E., see Whitford, C.A. (138) 327
Timmerman, H., see Van der Werf, J.F. (138) 199
Tsang, R., see Capasso, F. (138) 107
Tucci, I., see Barone, P. (138) 141
Tuisl, E., see Freissmuth, M. (138) 137
Tullii, M., see Wu, H.-Q. (138) 309
Tyano, S., see Weizman, R. (138) 289
Tyers, M.B., see Hagan, R.M. (138) 303
Tzigaret, C., see Moraru, I.I. (138) 427

Ueda, H., Misawa, H., Fukushima, N. and Takagi, H.
The specific opioid κ-agonist U-50,488H inhibits low Km GTPase (138) 129
Ueki, I.F., see Tamaoki, J. (138) 421
Ushijima, I., Mizuki, Y., Soeda, K., Kishimoto, O., Hara, T. and Yamada, M.
Effects of age on behavioral responses to dopamine agonists in the rat (138) 101

Vallgren, S., see Ekelund, M. (138) 225
Van den Akker, J., see Den Hertog, A. (138) 367
Van der Vliet, A., see Van der Werf, J.F. (138) 199
Van der Werf, J.F., Bast, A., Bijloo, G.J., Van der Vliet, A. and Timmerman, H.
HA autoreceptor assay with superfused slices of rat brain cortex and electrical stimulation (138) 199
Vezzani, A., see Wu, H.-Q. (138) 309
Vidulescu, C., see Moraru, I.I. (138) 427

Wamsley, J.K., see Filloux, F.M. (138) 61
Wang, S.S., Ricaurte, G.A. and Peroutka, S.J.
[^{3}H]3,4-Methylenedioxymethamphetamine (MDMA) interactions with brain membranes and glass fiber filter paper (138) 439
Wardley-Smith, B., Meldrum, B.S. and Halsey, M.J.
The effect of two novel dipeptide antagonists of excitatory amino acid neurotransmission on the high pressure neurological syndrome in the rat (138) 417
Watts, J. and Maiorano, L.
Effects of diltiazem upon globally ischemic rat hearts (138) 335
Weber, E., see Campbell, B.G. (138) 447
Weinger, M.B., see Stevens, C.W. (138) 299
Weizman, R., Tanne, Z., Granek, M., Karp, L., Golomb, M., Tyano, S. and Gavish, M.
Peripheral benzodiazepine binding sites on platelet mem-

branes are increased during diazepam treatment of anxious patients (138) 289
Whitford, C.A., Candy, J.M., Snell, C.R., Hirst, B.H., Oakley, A.E., Johnson, M. and Thompson, J.E.
Autoradiographic visualization of binding sites for [^{3}H]somatostatin in the rat brain (138) 327
Wiederhold, K.-H., see Palacios, J.M. (138) 273
Wieland, T., see Raymond, G. (138) 21
Wisnewsky, C., see Nokin, P. (138) 277
Wood, D.M. and Emmett-Oglesby, M.W.
Evidence for dopaminergic involvement in tolerance to the discriminative stimulus properties of cocaine (138) 155
Worms, P., Chambon, J.-P. and Biziere, K.
Behavioural evidence for a selective GABA-A antagonistic activity of SR 95103 and SR 42641 after intrastriatal injection in mice (138) 343
Wu, H.-Q., Tullii, M., Samanin, R. and Vezzani, A.
Norepinephrine modulates seizures induced by quinolinic acid in rats: selective and distinct roles of α-adrenoceptor subtypes (138) 309

Yaksh, T.L., see Stevens, C.W. (138) 299
Yamada, M., see Ushijima, I. (138) 101

Zhang, S.-y., McGaugh, J.L., Juler, R.G. and Introini-Collison, I.B.
Naloxone and [Met^5]enkephalin effects on retention: attenuation by adrenal denervation (138) 37

European Journal of Pharmacology, 138 (1987) 457–467
Elsevier

KEYWORD INDEX

A_2-adenosine receptors
Adenylate cyclase; Tubules; Methylxanthines (Freissmuth, M. (138) 137)

Acetylcholine
Phospholipase C; Smooth muscle contraction; Histamine; Prostaglandin $F_{2\alpha}$; Phosphoinositide turnover (Moraru, I.I. (138) 427)

Adenosine A_1 receptors
[^{3}H]Cyclohexyladenosine; Kidney; Glomeruli; Autoradiography (Palacios, J.M. (138) 273)

Adenylate cyclase
D-1 dopamine receptors; D-2 dopamine receptors; SCH 23390; (−)Sulpiride (Up-regulation) (Memo, M. (138) 45)

A_2-adenosine receptors; Tubules; Methylxanthines (Freissmuth, M. (138) 137)

Somatostatin receptors; CNS primary cultures; Pituitary membranes (Binding) (Chneiweiss, H. (138) 249)

Adrenal denervation
Naloxone; [Met^5]enkephalin; Inhibitory avoidance; Y-maze discrimination reversal; Memory (Mouse, Retention) (Zhang, S.-y. (138) 37)

Adrenal medulla
Pithed SHR; Pithed WKY; Cyclic AMP (plasma); Blood pressure; β-Adrenoceptors (Bucher, B. (138) 233)

Adrenoceptors
Quinolinic acid; Hippocampus; Electroencephalographic seizures; Norepinephrine (Wu, H.-Q. (138) 309)

α_2-Adrenoceptors
Clonidine; Pithed rats; Guanabenz; Plasma noradrenaline (Finberg, J.P.M. (138) 95)

Opiate receptors; Clonidine; Morphine; Antinociception; Spinal cord (Sullivan, A.F. (138) 169)

α-Adrenoceptors
Dihydroergotoxine; Dopamine receptors; Presynaptic receptors (Roquebert, J. (138) 433)

β-Adrenoceptors
Pithed SHR; Pithed WKY; Cyclic AMP (plasma); Blood pressure; Adrenal medulla (Bucher, B. (138) 233)

Aging
Bromocriptine; Apomorphine; Yawning; Stereotypy; Dopamine receptor activities (Ushijima, I. (138) 101)

Airway microvascular leakage
PAF; Thrombocytopaenia; Colloidal carbon tracer (Guinea-pig) (O'Donnell, S.R. (138) 385)

Airway responsiveness
Lung macrophages; Thromboxane A_2; Parasympathetic augmentation (Tamaoki, J. (138) 421)

Airways hyper-reactivity
Sensory fibers; Theophyllines; Capsaicin (Manzini, S. (138) 375)

Airway smooth muscle
Leukotrienes; FPL55712; Trachea; Leukotriene analogs (Guinea-pig) (Snyder, D.W. (138) 397)

Amiodarone
Thyroid hormones; Isoenzymes; Myosin (cardiac) (Rat) (Nokin, P. (138) 277)

Analgesia
Nefopam; Nociception; Serotonin; Hot plate; Formalin test (Hunskaar, S. (138) 77)

Antamanide
Phalloidin; Inotropic effect (negative); Potassium conductance (Frog) (Raymond, G. (138) 21)

Antianginal drugs
^{22}Na uptake; Brain synaptosomes; Heart muscle cells; Na^+ channel (Rat) (Grima, M. (138) 1)

Anticholinergic drugs
H_2-receptor antagonists; Atropine; Pirenzepine; Gastric acid secretion (Ekelund, M. (138) 225)

Antidepressants
5-HT_{1A} agonists; 5-HT_{1B} agonists; 8-OH-DPAT; Buspirone; TVXQ 7821 (ipsapirone); RU 24969; Depression; 5-HT; Stress (Kennett, G.A. (138) 53)

[^{3}H]Imipramine binding sites (high-affinity, low-affinity); Frontal cortex; 5-HT uptake; 5-HT levels; 5-HIAA levels; NE levels (Rat) (Hrdina, P.D. (138) 159)

Antinociception
α_2-Adrenoceptors; Opiate receptors; Clonidine; Morphine; Spinal cord (Sullivan, A.F. (138) 169)

Anxiolytics
Drug discrimination; 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OHDPAT); Serotonin$_{1A}$ receptors; Serotonin (Cunningham, K.A. (138) 29)

Apomorphine
Bromocriptine; Yawning; Stereotypy; Aging; Dopamine receptor activities (Ushijima, I. (138) 101)

Drug discrimination; Cocaine; Tolerance (Rat) (Wood, D.M. (138) 155)

Arachidonic acid
Cytochrome P450; Epoxides; Vasodilatation (Carroll, M.A. (138) 281)

Astrocyte cultures
Cerebellar granule cell cultures; Kainic acid; Excitatory amino acid receptors; Glutamate release; GABA release (Gallo, V. (138) 293)

ATP
Diltiazem; Ca^{2+} antagonists; Ischemia; Energy metabolism; Lactic acid (Watts, J. (138) 335)

ATP analogues
Portal vein; Sucrose gap; P_2-purinoceptor subtypes (Rat) (Reilly, W.M. (138) 319)

Atropine
H_2-receptor antagonists; Pirenzepine; Anticholinergic drugs; Gastric acid secretion (Ekelund, M. (138) 225)

Autoradiography
D-2 dopamine receptors; Substantia nigra; 6-Hydroxydopamine; Ibotenic acid; Autoreceptors; Sulpiride (Filloux, F.M. (138) 61)

[^{3}H]Cyclohexyladenosine; Adenosine A_1 receptors; Kidney; Glomeruli (Palacios, J.M. (138) 273)

Somatostatin; Receptors; Brain (Whitford, C.A. (138) 327)

Autoreceptors
D-2 dopamine receptors; Substantia nigra; 6-Hydroxydopamine; Ibotenic acid; Sulpiride; Autoradiography (Filloux, F.M. (138) 61)

BAM 18
Proenkephalin A; Metorphamide; Opioid peptides; Opioid receptors (Hurlbut, D.E. (138) 359)

Bepridil
Valproate; Na^+ conductance; Na^+ channels (*Myxicola* giant axon) (Schauf, C.L. (138) 89)

Blood pressure
Pithed SHR; Pithed WKY; Cyclic AMP (plasma); Adrenal medulla; β-Adrenoceptors (Bucher, B. (138) 233)

BN 52021
Proteinuria; PAF-acether antagonists; Triazolobenzodiazepines (Egido, J. (138) 119)

Brain
Somatostatin; Receptors; Autoradiography (Whitford, C.A. (138) 327)

Brain areas
Methylenedioxymethamphetamine; 5-Hydroxytryptamine; Dopamine; Norepinephrine (Mokler, D.J. (138) 265)

Brain synaptosomes
^{22}Na uptake; Heart muscle cells; Antianginal drugs; Na^+ channel (Rat) (Grima, M. (138) 1)

Bromocriptine
Apomorphine; Yawning; Stereotypy; Aging; Dopamine receptor activities (Ushijima, I. (138) 101)

Buspirone
5-HT$_{1A}$ agonists; 5-HT$_{1B}$ agonists; 8-OH-DPAT; TVXQ 7821 (ipsapirone); RU 24969; Antidepressants; Depression; 5-HT; Stress (Kennett, G.A. (138) 53)

BW 755C
Intestinal secretagogues; Gut tissue; Indomethacin (Capasso, F. (138) 107)

Ca^{2+} antagonists
Diltiazem; Ischemia; Energy metabolism; ATP; Lactic acid (Watts, J. (138) 335)

Ca current
Histamine; Single ventricular cell; H_2-receptors (Muramatsu, I. (138) 269)

Calcium antagonists
SHR; Vascular smooth muscle (Lindner, V. (138) 147)

Calcium channel antagonists
Despair test; Imipramine; Mianserin; Citalopram; Oxaprotiline ((+) and (−)) (Mogilnicka, E. (138) 413)

Calcium channels
Smooth muscle cells; Taenia caeci; α_1-Receptors; Mebeverine (Den Hertog, A. (138) 367)

Capsaicin
Airways hyper-reactivity; Sensory fibers; Theophyllines (Manzini, S. (138) 375)

β-Carbolines
β-CCM; DMCM; Positron emission tomography (PET); Receptor occupancy; Convulsive seizure (Primate) (Hantraye, P. (138) 239)

β-CCM
β-Carbolines; DMCM; Positron emission tomography (PET); Receptor occupancy; Convulsive seizure (Primate) (Hantraye, P. (138) 239)

Cerebellar granule cell cultures
Astrocyte cultures; Kainic acid; Excitatory amino acid receptors; Glutamate release; GABA release (Gallo, V. (138) 293)

p-Chlorophenylalanine
LY 165163; Feeding; 5-Hydroxytryptamine stereotypy; 5-HT_{1A} agonists; 5-HT receptors (Hutson, P.H. (138) 215)

Circling
6-Hydroxydopamine; Stereotypy; SKF 38393; Lisuride (Stereotaxic injection) (Fletcher, G.H. (138) 407)

Citalopram
Despair test; Calcium channel antagonists; Imipramine; Mianserin; Oxaprotiline ((+) and (−)) (Mogilnicka, E. (138) 413)

Clonidine
Pithed rats; Guanabenz; Plasma noradrenaline; α_2-Adrenoceptors (Finberg, J.P.M. (138) 95)

α_2-Adrenoceptors; Opiate receptors; Morphine; Antinociception; Spinal cord (Sullivan, A.F. (138) 169)

8-OH-DPAT; Ipsapirone; Idazoxan; Sympathetic nerve activity (preganglionic); 5-HT_{1A} receptors (Ramage, A.G. (138) 179)

CNS primary cultures
Somatostatin receptors; Adenylate cyclase; Pituitary membranes (Binding) (Chneiweiss, H. (138) 249)

Cocaine
Drug discrimination; Tolerance; Apomorphine (Rat) (Wood, D.M. (138) 155)

Colloidal carbon tracer
PAF; Airway microvascular leakage; Thrombocytopaenia (Guinea-pig) (O'Donnell, S.R. (138) 385)

Convulsive seizure
β-Carbolines; β-CCM; DMCM; Positron emission tomography (PET); Receptor occupancy (Primate) (Hantraye, P. (138) 239)

Co-transmission
Vas deferens; Reserpine; Purinergic; Endogenous release of ATP; Sympathetic nerves (Guinea-pig) (Kirkpatrick, K. (138) 207)

Cyclic AMP (plasma)
Pithed SHR; Pithed WKY; Blood pressure; Adrenal medulla; β-Adrenoceptors (Bucher, B. (138) 233)

Cytochrome P450
Arachidonic acid; Epoxides; Vasodilatation (Carroll, M.A. (138) 281)

D-1 dopamine receptors
D-2 dopamine receptors; SCH 23390; (−)Sulpiride; Adenylate cyclase (Up-regulation) (Memo, M. (138) 45)

D-2 dopamine receptors
D-1 dopamine receptors; SCH 23390; (−)Sulpiride; Adenylate cyclase (Up-regulation) (Memo, M. (138) 45)

Substantia nigra; 6-Hydroxydopamine; Ibotenic acid; Autoreceptors; Sulpiride; Autoradiography (Filloux, F.M. (138) 61)

D-1 dopamine receptors
[^{125}I]SCH 23982; Quinolinic acid; Striatal lesion; Dopamine receptor interactions (Barone, P. (138) 141)

Dehydroemetine
Emetine; Neuromuscular transmission; Endplate current; Quantal content (Alkadhi, K.A. (138) 257)

Depression
5-HT_{1A} agonists; 5-HT_{1B} agonists; 8-OH-DPAT; Buspirone; TVXQ 7821 (ipsapirone); RU 24969; Antidepressants; 5-HT; Stress (Kennett, G.A. (138) 53)

Despair test
Calcium channel antagonists; Imipramine; Mianserin; Citalopram; Oxaprotiline ((+) and (−)) (Mogilnicka, E. (138) 413)

Diazepam
Peripheral benzodiazepine binding sites; Generalized anxiety disorder; [^{3}H]PK 11195 (Weizman, R. (138) 289)

Dihydroergotoxine
α-Adrenoceptors; Dopamine receptors; Presynaptic receptors (Roquebert, J. (138) 433)

Diltiazem
Ca^{2+} antagonists; Ischemia; Energy metabolism; ATP; Lactic acid (Watts, J. (138) 335)

DMCM
β-Carbolines; β-CCM; Positron emission tomography (PET); Receptor occupancy; Convulsive seizure (Primate) (Hantraye, P. (138) 239)

DOB
Trachea; 5-HT_2 receptors; Hallucinogens (Heller, W.A. (138) 115)

Dopamine
Methylenedioxymethamphetamine; 5-Hydroxytryptamine; Norepinephrine; Brain areas (Mokler, D.J. (138) 265)

Dopamine receptor activities
Bromocriptine; Apomorphine; Yawning; Stereotypy; Aging (Ushijima, I. (138) 101)

Dopamine receptor interactions
D-1 dopamine receptors; [^{125}I]SCH 23982; Quinolinic acid; Striatal lesion (Barone, P. (138) 141)

Dopamine receptors
Dihydroergotoxine; α-Adrenoceptors; Presynaptic receptors (Roquebert, J. (138) 433)

Dopamine receptors (presynaptic)
Dopamine release (endogenous); Striatal slices; Veratrine; Nomifensine; HPLC (Herdon, H. (138) 69)

Dopamine release (endogenous)
Striatal slices; Dopamine receptors (presynaptic); Veratrine; Nomifensine; HPLC (Herdon, H. (138) 69)

Drug discrimination
Anxiolytics; 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OHDPAT); Serotonin$_{1A}$ receptors; Serotonin (Cunningham, K.A. (138) 29)

Cocaine; Tolerance; Apomorphine (Rat) (Wood, D.M. (138) 155)

Dynorphin A-(1-17)
U50488; κ Opiates; Motor dysfunction (Intrathecal administration) (Stevens, C.W. (138) 299)

Electroencephalographic seizures
Quinolinic acid; Hippocampus; Norepinephrine; Adrenoceptors (Wu, H.-Q. (138) 309)

Emetine
Dehydroemetine; Neuromuscular transmission; Endplate current; Quantal content (Alkadhi, K.A. (138) 257)

Endogenous release of ATP
Vas deferens; Co-transmission; Reserpine; Purinergic; Sympathetic nerves (Guinea-pig) (Kirkpatrick, K. (138) 207)

Endplate current
Emetine; Dehydroemetine; Neuromuscular transmission; Quantal content (Alkadhi, K.A. (138) 257)

Energy metabolism
Diltiazem; Ca^{2+} antagonists; Ischemia; ATP; Lactic acid (Watts, J. (138) 335)

Epoxides
Arachidonic acid; Cytochrome P450; Vasodilatation (Carroll, M.A. (138) 281)

N-Ethyl-3,4-dioxyamphetamine
3,4-Methylenedioxyamphetamine; 3,4-Methylenedioxymethamphetamine; Methamphetamine; Neurotensin (Merchant, K.M. (138) 151)

N-Ethylmaleimide
Substance P receptors; Physalaemin; Guanine nucleotides; GTP binding regulatory protein (Divalent cations) (Sharma, P.M. (138) 9)

Excitatory amino acid antagonists
High pressure neurological syndrome; NMDA-preferring receptor (Wardley-Smith, B. (138) 417)

Excitatory amino acid receptors
Astrocyte cultures; Cerebellar granule cell cultures; Kainic acid; Glutamate release; GABA release (Gallo, V. (138) 293)

Explosive motor behavior
GABA blockade; Morphine; Periaqueductal gray (Rat) (Jacquet, Y.F. (138) 285)

Feeding
LY 165163; 5-Hydroxytryptamine stereotypy; 5-HT$_{1A}$ agonists; 5-HT receptors; p-Chlorophenylalanine (Hutson, P.H. (138) 215)

Formalin test
Nefopam; Nociception; Analgesia; Serotonin; Hot plate (Hunskaar, S. (138) 77)

FPL55712
Leukotrienes; Airway smooth muscle; Trachea; Leukotriene analogs (Guinea-pig) (Snyder, D.W. (138) 397)

Frontal cortex
[^{3}H]Imipramine binding sites (high-affinity, low-affinity); Antidepressants; 5-HT uptake; 5-HT levels; 5-HIAA levels; NE levels (Rat) (Hrdina, P.D. (138) 159)

GABA blockade
Morphine; Explosive motor behavior; Periaqueductal gray (Rat) (Jacquet, Y.F. (138) 285)

GABA$_A$ receptor antagonists
SR 95103; SR 42641; Turning behaviour; Striatum; Glycine (Worms, P. (138) 343)

GABA release
Astrocyte cultures; Cerebellar granule cell cultures; Kainic acid; Excitatory amino acid receptors; Glutamate release (Gallo, V. (138) 293)

Gastric acid secretion
H_2-receptor antagonists; Atropine; Pirenzepine; Anticholinergic drugs (Ekelund, M. (138) 225)

Generalized anxiety disorder
Peripheral benzodiazepine binding sites; Diazepam; [^{3}H]PK 11195 (Weizman, R. (138) 289)

Glomeruli
[^{3}H]Cyclohexyladenosine; Adenosine A_1 receptors; Kidney; Autoradiography (Palacios, J.M. (138) 273)

Glutamate release
Astrocyte cultures; Cerebellar granule cell cultures; Kainic acid; Excitatory amino acid receptors; GABA release (Gallo, V. (138) 293)

Glycine
$GABA_A$ receptor antagonists; SR 95103; SR 42641; Turning behaviour; Striatum (Worms, P. (138) 343)

GTPase (low Km)
U-50,488H; Opioid κ-receptor (Ueda, H. (138) 129)

GTP binding regulatory protein
Substance P receptors; Physalaemin; Guanine nucleotides; N-Ethylmaleimide (Divalent cations) (Sharma, P.M. (138) 9)

Guanabenz
Clonidine; Pithed rats; Plasma noradrenaline; α_2-Adrenoceptors (Finberg, J.P.M. (138) 95)

Guanine nucleotides
Substance P receptors; Physalaemin; GTP binding regulatory protein; N-Ethylmaleimide (Divalent cations) (Sharma, P.M. (138) 9)

Gut tissue
Intestinal secretagogues; Indomethacin; BW 755C (Capasso, F. (138) 107)

HA autoreceptors
Histamine; H_3 receptors (Superfused H_3 assay) (Van der Werf, J.F. (138) 199)

Hallucinogens
Trachea; 5-HT_2 receptors; DOB (Heller, W.A. (138) 115)

[^{3}H]Cyclohexyladenosine
Adenosine A_1 receptors; Kidney; Glomeruli; Autoradiography (Palacios, J.M. (138) 273)

Heart muscle cells
^{22}Na uptake; Brain synaptosomes; Antianginal drugs; Na^+ channel (Rat) (Grima, M. (138) 1)

5-HIAA levels
[^{3}H]Imipramine binding sites (high-affinity, low-affinity); Frontal cortex; Antidepressants; 5-HT uptake; 5-HT levels; NE levels (Rat) (Hrdina, P.D. (138) 159)

High pressure neurological syndrome
Excitatory amino acid antagonists; NMDA-preferring receptor (Wardley-Smith, B. (138) 417)

[^{3}H]Imipramine binding sites (high-affinity, low-affinity)
Frontal cortex; Antidepressants; 5-HT uptake; 5-HT levels; 5-HIAA levels; NE levels (Rat) (Hrdina, P.D. (138) 159)

Hippocampus
Quinolinic acid; Electroencephalographic seizures; Norepinephrine; Adrenoceptors (Wu, H.-Q. (138) 309)

Histamine
HA autoreceptors; H_3 receptors (Superfused H_3 assay) (Van der Werf, J.F. (138) 199)

Single ventricular cell; Ca current; H_2-receptors (Muramatsu, I. (138) 269)

Phospholipase C; Smooth muscle contraction; Acetylcholine; Prostaglandin $F_{2\alpha}$; Phosphoinositide turnover (Moraru, I.I. (138) 427)

Hot plate
Nefopam; Nociception; Analgesia; Serotonin; Formalin test (Hunskaar, S. (138) 77)

[^{3}H]PK 11195
Peripheral benzodiazepine binding sites; Generalized anxiety disorder; Diazepam (Weizman, R. (138) 289)

HPLC
Dopamine release (endogenous); Striatal slices; Dopamine receptors (presynaptic); Veratrine; Nomifensine (Herdon, H. (138) 69)

H_2-receptor antagonists
Atropine; Pirenzepine; Anticholinergic drugs; Gastric acid secretion (Ekelund, M. (138) 225)

H_3 receptors
Histamine; HA autoreceptors (Superfused H_3 assay) (Van der Werf, J.F. (138) 199)

H_2-receptors
Histamine; Single ventricular cell; Ca current (Muramatsu, I. (138) 269)

5-HT
5-HT_{1A} agonists; 5-HT_{1B} agonists; 8-OH-DPAT; Buspirone; TVXQ 7821 (ipsapirone); RU 24969; Antidepressants; Depression; Stress (Kennett, G.A. (138) 53)

5-HT_{1A} agonists
5-HT_{1B} agonists; 8-OH-DPAT; Buspirone; TVXQ 7821 (ipsapirone); RU 24969; Antidepressants; Depression; 5-HT; Stress (Kennett, G.A. (138) 53)

5-HT$_{1B}$ agonists
5-HT$_{1A}$ agonists; 8-OH-DPAT; Buspirone; TVXQ 7821 (ipsapirone); RU 24969; Antidepressants; Depression; 5-HT; Stress (Kennett, G.A. (138) 53)

5-HT$_{1A}$ agonists
LY 165163; Feeding; 5-Hydroxytryptamine stereotypy; 5-HT receptors; p-Chlorophenylalanine (Hutson, P.H. (138) 215)

5-HT levels
[^{3}H]Imipramine binding sites (high-affinity, low-affinity); Frontal cortex; Antidepressants; 5-HT uptake; 5-HIAA levels; NE levels (Rat) (Hrdina, P.D. (138) 159)

5-HT$_2$ receptors
Trachea; Hallucinogens; DOB (Heller, W.A. (138) 115)

5-HT$_{1A}$ receptors
8-OH-DPAT; Ipsapirone; Clonidine; Idazoxan; Sympathetic nerve activity (preganglionic) (Ramage, A.G. (138) 179)

5-HT receptors
LY 165163; Feeding; 5-Hydroxytryptamine stereotypy; 5-HT$_{1A}$ agonists; p-Chlorophenylalanine (Hutson, P.H. (138) 215)

5-HT uptake
[^{3}H]Imipramine binding sites (high-affinity, low-affinity); Frontal cortex; Antidepressants; 5-HT levels; 5-HIAA levels; NE levels (Rat) (Hrdina, P.D. (138) 159)

8-Hydroxy-2-(di-n-propylamino)tetralin (8-OHDPAT)
Anxiolytics; Drug discrimination; Serotonin$_{1A}$ receptors; Serotonin (Cunningham, K.A. (138) 29)

6-Hydroxydopamine
D-2 dopamine receptors; Substantia nigra; Ibotenic acid; Autoreceptors; Sulpiride; Autoradiography (Filloux, F.M. (138) 61)

Noradrenaline; Substance P; Sensory ganglia; Trigeminal (Nielsch, U. (138) 193)

Circling; Stereotypy; SKF 38393; Lisuride (Stereotaxic injection) (Fletcher, G.H. (138) 407)

5-Hydroxytryptamine
Methylenedioxymethamphetamine; Dopamine; Norepinephrine; Brain areas (Mokler, D.J. (138) 265)

5-Hydroxytryptamine stereotypy
LY 165163; Feeding; 5-HT$_{1A}$ agonists; 5-HT receptors; p-Chlorophenylalanine (Hutson, P.H. (138) 215)

Hypertensive response
Renin; Renin-angiotensin system (brain); SHR (Kawasaki, H. (138) 351)

Ibotenic acid
D-2 dopamine receptors; Substantia nigra; 6-Hydroxydopamine; Autoreceptors; Sulpiride; Autoradiography (Filloux, F.M. (138) 61)

Idazoxan
8-OH-DPAT; Ipsapirone; Clonidine; Sympathetic nerve activity (preganglionic); 5-HT$_{1A}$ receptors (Ramage, A.G. (138) 179)

Imipramine
Despair test; Calcium channel antagonists; Mianserin; Citalopram; Oxaprotiline ((+) and (−)) (Mogilnicka, E. (138) 413)

Indomethacin
Intestinal secretagogues; Gut tissue; BW 755C (Capasso, F. (138) 107)

Inhibitory avoidance
Naloxone; [Met^5]enkephalin; Y-maze discrimination reversal; Memory; Adrenal denervation (Mouse, Retention) (Zhang, S.-y. (138) 37)

Inotropic effect (negative)
Antamanide; Phalloidin; Potassium conductance (Frog) (Raymond, G. (138) 21)

Intestinal secretagogues
Gut tissue; Indomethacin; BW 755C (Capasso, F. (138) 107)

Ipsapirone
8-OH-DPAT; Clonidine; Idazoxan; Sympathetic nerve activity (preganglionic); 5-HT$_{1A}$ receptors (Ramage, A.G. (138) 179)

[^{125}I]SCH 23982
D-1 dopamine receptors; Quinolinic acid; Striatal lesion; Dopamine receptor interactions (Barone, P. (138) 141)

Ischemia
Diltiazem; Ca^{2+} antagonists; Energy metabolism; ATP; Lactic acid (Watts, J. (138) 335)

Isoenzymes
Amiodarone; Thyroid hormones; Myosin (cardiac) (Rat) (Nokin, P. (138) 277)

Kainic acid
Astrocyte cultures; Cerebellar granule cell cultures; Excitatory amino acid receptors; Glutamate release; GABA release (Gallo, V. (138) 293)

Kidney
[^{3}H]Cyclohexyladenosine; Adenosine A_1 receptors; Glomeruli; Autoradiography (Palacios, J.M. (138) 273)

Lactic acid
Diltiazem; Ca^{2+} antagonists; Ischemia; Energy metabolism; ATP (Watts, J. (138) 335)

Leukotriene analogs
Leukotrienes; FPL55712; Airway smooth muscle; Trachea (Guinea-pig) (Snyder, D.W. (138) 397)

Leukotrienes
FPL55712; Airway smooth muscle; Trachea; Leukotriene analogs (Guinea-pig) (Snyder, D.W. (138) 397)

Lisuride
6-Hydroxydopamine; Circling; Stereotypy; SKF 38393 (Stereotaxic injection) (Fletcher, G.H. (138) 407)

Lung macrophages
Thromboxane A_2; Airway responsiveness; Parasympathetic augmentation (Tamaoki, J. (138) 421)

LY 165163
Feeding; 5-Hydroxytryptamine stereotypy; 5-HT_{1A} agonists; 5-HT receptors; p-Chlorophenylalanine (Hutson, P.H. (138) 215)

Mebeverine
Smooth muscle cells; Taenia caeci; α_1-Receptors; Calcium channels (Den Hertog, A. (138) 367)

Memory
Naloxone; [Met^5]enkephalin; Inhibitory avoidance; Y-maze discrimination reversal; Adrenal denervation (Mouse, Retention) (Zhang, S.-y. (138) 37)

[Met^5]enkephalin
Naloxone; Inhibitory avoidance; Y-maze discrimination reversal; Memory; Adrenal denervation (Mouse, Retention) (Zhang, S.-y. (138) 37)

Methamphetamine
3,4-Methylenedioxyamphetamine; 3,4-Methylenedioxymethamphetamine; N-Ethyl-3,4-dioxyamphetamine; Neurotensin (Merchant, K.M. (138) 151)

N-Methyl-D-aspartate
Naloxone; Neurotoxicity; Neocortex (Cell culture) (Kim, J.P. (138) 133)

3,4-Methylenedioxyamphetamine
3,4-Methylenedioxymethamphetamine; N-Ethyl-3,4-dioxyamphetamine; Methamphetamine; Neurotensin (Merchant, K.M. (138) 151)

3,4-Methylenedioxymethamphetamine
3,4-Methylenedioxyamphetamine; N-Ethyl-3,4-dioxyamphetamine; Methamphetamine; Neurotensin (Merchant, K.M. (138) 151)

Methylenedioxymethamphetamine
5-Hydroxytryptamine; Dopamine; Norepinephrine; Brain areas (Mokler, D.J. (138) 265)

3,4-Methylenedioxymethamphetamine (MDMA)
Radioligand binding studies; Polyethylenimine (Artifactual binding) (Wang, S.S. (138) 439)

Methylxanthines
A_2-adenosine receptors; Adenylate cyclase; Tubules (Freissmuth, M. (138) 137)

Metorphamide
BAM 18; Proenkephalin A; Opioid peptides; Opioid receptors (Hurlbut, D.E. (138) 359)

Mianserin
Despair test; Calcium channel antagonists; Imipramine; Citalopram; Oxaprotiline ((+) and (−)) (Mogilnicka, E. (138) 413)

Morphine
α_2-Adrenoceptors; Opiate receptors; Clonidine; Antinociception; Spinal cord (Sullivan, A.F. (138) 169)

GABA blockade; Explosive motor behavior; Periaqueductal gray (Rat) (Jacquet, Y.F. (138) 285)

Motor dysfunction
Dynorphin A-(1-17); U50488; κ Opiates (Intrathecal administration) (Stevens, C.W. (138) 299)

Muscarinic receptors
Submandibular gland; Urinary bladder; QNB (Batra, S. (138) 83)

Myosin (cardiac)
Amiodarone; Thyroid hormones; Isoenzymes (Rat) (Nokin, P. (138) 277)

Na^+ channel
^{22}Na uptake; Brain synaptosomes; Heart muscle cells; Antianginal drugs (Rat) (Grima, M. (138) 1)

Na^+ channels
Bepridil; Valproate; Na^+ conductance (*Myxicola* giant axon) (Schauf, C.L. (138) 89)

Na^+ conductance
Bepridil; Valproate; Na^+ channels (*Myxicola* giant axon) (Schauf, C.L. (138) 89)

Naloxone
[Met^5]enkephalin; Inhibitory avoidance; Y-maze discrimination reversal; Memory; Adrenal denervation (Mouse, Retention) (Zhang, S.-y. (138) 37)

N-Methyl-D-aspartate; Neurotoxicity; Neocortex (Cell culture) (Kim, J.P. (138) 133)

^{22}Na uptake
Brain synaptosomes; Heart muscle cells; Antianginal drugs; Na^+ channel (Rat) (Grima, M. (138) 1)

Nefopam
Nociception; Analgesia; Serotonin; Hot plate; Formalin test (Hunskaar, S. (138) 77)

NE levels
[^{3}H]Imipramine binding sites (high-affinity, low-affinity); Frontal cortex; Antidepressants; 5-HT uptake; 5-HT levels; 5-HIAA levels (Rat) (Hrdina, P.D. (138) 159)

Neocortex
Naloxone; N-Methyl-D-aspartate; Neurotoxicity (Cell culture) (Kim, J.P. (138) 133)

Neurokinin A
Substance P; Neurokinin B (Binding affinities, Biological activities) (Dion, S. (138) 125)

Neurokinin B
Substance P; Neurokinin A (Binding affinities, Biological activities) (Dion, S. (138) 125)

Neuromuscular transmission
Emetine; Dehydroemetine; Endplate current; Quantal content (Alkadhi, K.A. (138) 257)

Neurotensin
3,4-Methylenedioxyamphetamine; 3,4-Methylenedioxymethamphetamine; N-Ethyl-3,4-dioxyamphetamine; Methamphetamine (Merchant, K.M. (138) 151)

Neurotoxicity
Naloxone; N-Methyl-D-aspartate; Neocortex (Cell culture) (Kim, J.P. (138) 133)

NMDA-preferring receptor
Excitatory amino acid antagonists; High pressure neurological syndrome (Wardley-Smith, B. (138) 417)

Nociception
Nefopam; Analgesia; Serotonin; Hot plate; Formalin test (Hunskaar, S. (138) 77)

Nomifensine
Dopamine release (endogenous); Striatal slices; Dopamine receptors (presynaptic); Veratrine; HPLC (Herdon, H. (138) 69)

Noradrenaline
Substance P; Sensory ganglia; Trigeminal; 6-Hydroxydopamine (Nielsch, U. (138) 193)

Norepinephrine
Methylenedioxymethamphetamine; 5-Hydroxytryptamine; Dopamine; Brain areas (Mokler, D.J. (138) 265)

Quinolinic acid; Hippocampus; Electroencephalographic seizures; Adrenoceptors (Wu, H.-Q. (138) 309)

8-OH-DPAT
5-HT_{1A} agonists; 5-HT_{1B} agonists; Buspirone; TVXQ 7821 (ipsapirone); RU 24969; Antidepressants; Depression; 5-HT; Stress (Kennett, G.A. (138) 53)

Ipsapirone; Clonidine; Idazoxan; Sympathetic nerve activity (preganglionic); 5-HT_{1A} receptors (Ramage, A.G. (138) 179)

Opiate receptors
α_2-Adrenoceptors; Clonidine; Morphine; Antinociception; Spinal cord (Sullivan, A.F. (138) 169)

κ Opiates
Dynorphin A-(1-17); U50488; Motor dysfunction (Intrathecal administration) (Stevens, C.W. (138) 299)

Opioid κ-receptor
U-50,488H; GTPase (low Km) (Ueda, H. (138) 129)

Opioid peptides
BAM 18; Proenkephalin A; Metorphamide; Opioid receptors (Hurlbut, D.E. (138) 359)

Opioid receptors
BAM 18; Proenkephalin A; Metorphamide; Opioid peptides (Hurlbut, D.E. (138) 359)

Oxaprotiline ((+) and (−))
Despair test; Calcium channel antagonists; Imipramine; Mianserin; Citalopram (Mogilnicka, E. (138) 413)

PAF
Airway microvascular leakage; Thrombocytopaenia; Colloidal carbon tracer (Guinea-pig) (O'Donnell, S.R. (138) 385)

PAF-acether antagonists
Proteinuria; BN 52021; Triazolobenzodiazepines (Egido, J. (138) 119)

Parasympathetic augmentation
Lung macrophages; Thromboxane A_2; Airway responsiveness (Tamaoki, J. (138) 421)

Periaqueductal gray
GABA blockade; Morphine; Explosive motor behavior (Rat) (Jacquet, Y.F. (138) 285)

Peripheral benzodiazepine binding sites
Generalized anxiety disorder; Diazepam; [^{3}H]PK 11195 (Weizman, R. (138) 289)

Phalloidin
Antamanide; Inotropic effect (negative); Potassium conductance (Frog) (Raymond, G. (138) 21)

Phosphoinositide turnover
Phospholipase C; Smooth muscle contraction; Acetylcholine; Histamine; Prostaglandin $F_{2\alpha}$ (Moraru, I.I. (138) 427)

Phospholipase C
Smooth muscle contraction; Acetylcholine; Histamine; Prostaglandin $F_{2\alpha}$; Phosphoinositide turnover (Moraru, I.I. (138) 427)

Physalaemin
Substance P receptors; Guanine nucleotides; GTP binding regulatory protein; N-Ethylmaleimide (Divalent cations) (Sharma, P.M. (138) 9)

Pirenzepine
H_2-receptor antagonists; Atropine; Anticholinergic drugs; Gastric acid secretion (Ekelund, M. (138) 225)

Pithed rats
Clonidine; Guanabenz; Plasma noradrenaline; α_2-Adrenoceptors (Finberg, J.P.M. (138) 95)

Pithed SHR
Pithed WKY; Cyclic AMP (plasma); Blood pressure; Adrenal medulla; β-Adrenoceptors (Bucher, B. (138) 233)

Pithed WKY
Pithed SHR; Cyclic AMP (plasma); Blood pressure; Adrenal medulla; β-Adrenoceptors (Bucher, B. (138) 233)

Pituitary membranes
Somatostatin receptors; Adenylate cyclase; CNS primary cultures (Binding) (Chneiweiss, H. (138) 249)

Plasma noradrenaline
Clonidine; Pithed rats; Guanabenz; α_2-Adrenoceptors (Finberg, J.P.M. (138) 95)

Polyethylenimine
3,4-Methylenedioxymethamphetamine (MDMA); Radioligand binding studies (Artifactual binding) (Wang, S.S. (138) 439)

Portal vein
ATP analogues; Sucrose gap; P_2-purinoceptor subtypes (Rat) (Reilly, W.M. (138) 319)

Positron emission tomography (PET)
β-Carbolines; β-CCM; DMCM; Receptor occupancy; Convulsive seizure (Primate) (Hantraye, P. (138) 239)

Potassium conductance
Antamanide; Phalloidin; Inotropic effect (negative) (Frog) (Raymond, G. (138) 21)

P_2-purinoceptor subtypes
ATP analogues; Portal vein; Sucrose gap (Rat) (Reilly, W.M. (138) 319)

Presynaptic receptors
Dihydroergotoxine; α-Adrenoceptors; Dopamine receptors (Roquebert, J. (138) 433)

Proenkephalin A
BAM 18; Metorphamide; Opioid peptides; Opioid receptors (Hurlbut, D.E. (138) 359)

Prostaglandin $F_{2\alpha}$
Phospholipase C; Smooth muscle contraction; Acetylcholine; Histamine; Phosphoinositide turnover (Moraru, I.I. (138) 427)

Proteinuria
PAF-acether antagonists; BN 52021; Triazolobenzodiazepines (Egido, J. (138) 119)

Purinergic
Vas deferens; Co-transmission; Reserpine; Endogenous release of ATP; Sympathetic nerves (Guinea-pig) (Kirkpatrick, K. (138) 207)

QNB
Muscarinic receptors; Submandibular gland; Urinary bladder (Batra, S. (138) 83)

Quantal content
Emetine; Dehydroemetine; Neuromuscular transmission; End-plate current (Alkadhi, K.A. (138) 257)

Quinolinic acid
D-1 dopamine receptors; [^{125}I]SCH 23982; Striatal lesion; Dopamine receptor interactions (Barone, P. (138) 141)

Hippocampus; Electroencephalographic seizures; Norepinephrine; Adrenoceptors (Wu, H.-Q. (138) 309)

Radioligand binding studies
3,4-Methylenedioxymethamphetamine (MDMA); Polyethylenimine (Artifactual binding) (Wang, S.S. (138) 439)

Receptor occupancy
β-Carbolines; β-CCM; DMCM; Positron emission tomography (PET); Convulsive seizure (Primate) (Hantraye, P. (138) 239)

Receptors
Somatostatin; Autoradiography; Brain (Whitford, C.A. (138) 327)

α_1-Receptors
Smooth muscle cells; Taenia caeci; Calcium channels; Mebeverine (Den Hertog, A. (138) 367)

Renin
Hypertensive response; Renin-angiotensin system (brain); SHR (Kawasaki, H. (138) 351)

Renin-angiotensin system (brain)
Renin; Hypertensive response; SHR (Kawasaki, H. (138) 351)

Reserpine
Vas deferens; Co-transmission; Purinergic; Endogenous release

of ATP; Sympathetic nerves (Guinea-pig) (Kirkpatrick, K. (138) 207)

RU 24969
5-HT_{1A} agonists; 5-HT_{1B} agonists; 8-OH-DPAT; Buspirone; TVXQ 7821 (ipsapirone); Antidepressants; Depression; 5-HT; Stress (Kennett, G.A. (138) 53)

SCH 23390
D-1 dopamine receptors; D-2 dopamine receptors; (−)Sulpiride; Adenylate cyclase (Up-regulation) (Memo, M. (138) 45)

Sensory fibers
Airways hyper-reactivity; Theophyllines; Capsaicin (Manzini, S. (138) 375)

Sensory ganglia
Noradrenaline; Substance P; Trigeminal; 6-Hydroxydopamine (Nielsch, U. (138) 193)

Serotonin
Anxiolytics; Drug discrimination; 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OHDPAT); Serotonin$_{1A}$ receptors (Cunningham, K.A. (138) 29)

Nefopam; Nociception; Analgesia; Hot plate; Formalin test (Hunskaar, S. (138) 77)

Serotonin$_{1A}$ receptors
Anxiolytics; Drug discrimination; 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OHDPAT); Serotonin (Cunningham, K.A. (138) 29)

SHR
Vascular smooth muscle; Calcium antagonists (Lindner, V. (138) 147)

Renin; Hypertensive response; Renin-angiotensin system (brain) (Kawasaki, H. (138) 351)

Single ventricular cell
Histamine; Ca current; H_2-receptors (Muramatsu, I. (138) 269)

SKF 38393
6-Hydroxydopamine; Circling; Stereotypy; Lisuride (Stereotaxic injection) (Fletcher, G.H. (138) 407)

Smooth muscle cells
Taenia caeci; α_1-Receptors; Calcium channels; Mebeverine (Den Hertog, A. (138) 367)

Smooth muscle contraction
Phospholipase C; Acetylcholine; Histamine; Prostaglandin $F_{2\alpha}$; Phosphoinositide turnover (Moraru, I.I. (138) 427)

Somatostatin
Receptors; Autoradiography; Brain (Whitford, C.A. (138) 327)

Somatostatin receptors
Adenylate cyclase; CNS primary cultures; Pituitary membranes (Binding) (Chneiweiss, H. (138) 249)

Spinal cord
α_2-Adrenoceptors; Opiate receptors; Clonidine; Morphine; Antinociception (Sullivan, A.F. (138) 169)

SR 42641
$GABA_A$ receptor antagonists; SR 95103; Turning behaviour; Striatum; Glycine (Worms, P. (138) 343)

SR 95103
$GABA_A$ receptor antagonists; SR 42641; Turning behaviour; Striatum; Glycine (Worms, P. (138) 343)

Stereotypy
Bromocriptine; Apomorphine; Yawning; Aging; Dopamine receptor activities (Ushijima, I. (138) 101)

6-Hydroxydopamine; Circling; SKF 38393; Lisuride (Stereotaxic injection) (Fletcher, G.H. (138) 407)

Stress
5-HT_{1A} agonists; 5-HT_{1B} agonists; 8-OH-DPAT; Buspirone; TVXQ 7821 (ipsapirone); RU 24969; Antidepressants; Depression; 5-HT (Kennett, G.A. (138) 53)

Striatal lesion
D-1 dopamine receptors; [^{125}I]SCH 23982; Quinolinic acid; Dopamine receptor interactions (Barone, P. (138) 141)

Striatal slices
Dopamine release (endogenous); Dopamine receptors (presynaptic); Veratrine; Nomifensine; HPLC (Herdon, H. (138) 69)

Striatum
$GABA_A$ receptor antagonists; SR 95103; SR 42641; Turning behaviour; Glycine (Worms, P. (138) 343)

Submandibular gland
Muscarinic receptors; Urinary bladder; QNB (Batra, S. (138) 83)

Substance P
Neurokinin A; Neurokinin B (Binding affinities, Biological activities) (Dion, S. (138) 125)

Noradrenaline; Sensory ganglia; Trigeminal; 6-Hydroxydopamine (Nielsch, U. (138) 193)

Substance P receptors
Physalaemin; Guanine nucleotides; GTP binding regulatory protein; N-Ethylmaleimide (Divalent cations) (Sharma, P.M. (138) 9)

Substantia nigra
D-2 dopamine receptors; 6-Hydroxydopamine; Ibotenic acid;

Autoreceptors; Sulpiride; Autoradiography (Filloux, F.M. (138) 61)

Sucrose gap
ATP analogues; Portal vein; P_2-purinoceptor subtypes (Rat) (Reilly, W.M. (138) 319)

(−)Sulpiride
D-1 dopamine receptors; D-2 dopamine receptors; SCH 23390; Adenylate cyclase (Up-regulation) (Memo, M. (138) 45)

Sulpiride
D-2 dopamine receptors; Substantia nigra; 6-Hydroxydopamine; Ibotenic acid; Autoreceptors; Autoradiography (Filloux, F.M. (138) 61)

Sympathetic nerve activity (preganglionic)
8-OH-DPAT; Ipsapirone; Clonidine; Idazoxan; 5-HT_{1A} receptors (Ramage, A.G. (138) 179)

Sympathetic nerves
Vas deferens; Co-transmission; Reserpine; Purinergic; Endogenous release of ATP (Guinea-pig) (Kirkpatrick, K. (138) 207)

Taenia caeci
Smooth muscle cells; α_1-Receptors; Calcium channels; Mebeverine (Den Hertog, A. (138) 367)

Theophyllines
Airways hyper-reactivity; Sensory fibers; Capsaicin (Manzini, S. (138) 375)

Thrombocytopaenia
PAF; Airway microvascular leakage; Colloidal carbon tracer (Guinea-pig) (O'Donnell, S.R. (138) 385)

Thromboxane A_2
Lung macrophages; Airway responsiveness; Parasympathetic augmentation (Tamaoki, J. (138) 421)

Thyroid hormones
Amiodarone; Isoenzymes; Myosin (cardiac) (Rat) (Nokin, P. (138) 277)

Tolerance
Drug discrimination; Cocaine; Apomorphine (Rat) (Wood, D.M. (138) 155)

Trachea
5-HT_2 receptors; Hallucinogens; DOB (Heller, W.A. (138) 115)

Leukotrienes; FPL55712; Airway smooth muscle; Leukotriene analogs (Guinea-pig) (Snyder, D.W. (138) 397)

Triazolobenzodiazepines
Proteinuria; PAF-acether antagonists; BN 52021 (Egido, J. (138) 119)

Trigeminal
Noradrenaline; Substance P; Sensory ganglia; 6-Hydroxydopamine (Nielsch, U. (138) 193)

Tubules
A_2-adenosine receptors; Adenylate cyclase; Methylxanthines (Freissmuth, M. (138) 137)

Turning behaviour
$GABA_A$ receptor antagonists; SR 95103; SR 42641; Striatum; Glycine (Worms, P. (138) 343)

TVXQ 7821 (ipsapirone)
5-HT_{1A} agonists; 5-HT_{1B} agonists; 8-OH-DPAT; Buspirone; RU 24969; Antidepressants; Depression; 5-HT; Stress (Kennett, G.A. (138) 53)

U50488
Dynorphin A-(1-17); κ Opiates; Motor dysfunction (Intrathecal administration) (Stevens, C.W. (138) 299)

U-50,488H
Opioid κ-receptor; GTPase (low Km) (Ueda, H. (138) 129)

Urinary bladder
Muscarinic receptors; Submandibular gland; QNB (Batra, S. (138) 83)

Valproate
Bepridil; Na^+ conductance; Na^+ channels (*Myxicola* giant axon) (Schauf, C.L. (138) 89)

Vascular smooth muscle
SHR; Calcium antagonists (Lindner, V. (138) 147)

Vas deferens
Co-transmission; Reserpine; Purinergic; Endogenous release of ATP; Sympathetic nerves (Guinea-pig) (Kirkpatrick, K. (138) 207)

Vasodilatation
Arachidonic acid; Cytochrome P450; Epoxides (Carroll, M.A. (138) 281)

Veratrine
Dopamine release (endogenous); Striatal slices; Dopamine receptors (presynaptic); Nomifensine; HPLC (Herdon, H. (138) 69)

Yawning
Bromocriptine; Apomorphine; Stereotypy; Aging; Dopamine receptor activities (Ushijima, I. (138) 101)

Y-maze discrimination reversal
Naloxone; [Met^5]enkephalin; Inhibitory avoidance; Memory; Adrenal denervation (Mouse, Retention) (Zhang, S.-y. (138) 37)

SCOPE OF THE JOURNAL

The EUROPEAN JOURNAL OF PHARMACOLOGY will consider manuscripts on the mechanisms of action of chemical substances affecting biological systems. MANUSCRIPTS SUBMITTED TO THE JOURNAL ARE ONLY ACCEPTED ON THE UNDERSTANDING THAT: (1) THEY ARE SUBJECT TO EDITORIAL REVIEW; (2) THEY HAVE NOT BEEN AND WILL NOT BE PUBLISHED IN WHOLE OR IN PART IN ANY OTHER JOURNAL; (3) THE RECOMMENDATIONS FROM THE DECLARATION OF HELSINKI AND THE INTERNATIONALLY ACCEPTED PRINCIPLES IN THE CARE AND USE OF EXPERIMENTAL ANIMALS HAVE BEEN ADHERED TO.

Editorial review

Rapid communications are evaluated by the Editorial Office and are either accepted or rejected. Full length manuscripts and Short communications are generally submitted to 2 referees who are chosen for their ability to evaluate the work. Authors may request that certain referees should not be chosen. Members of the Editorial Board will usually be called upon for advice when there is disagreement among the referees or between referees and authors, or when the editor believes that the manuscript has not received adequate consideration from the referees. In order to reduce mailing cost, manuscripts will not be returned. Only the decision of the Editorial Office, together with the advice of the referees will be sent to the author(s). Referees will be requested to keep the copy of the manuscript which they have received for evaluation, and to destroy it once they have been notified of the final decision concerning the manuscript. When authors submit a revised manuscript, they should reply to the comments of the referees, indicating which comments have been incorporated and the reasons for disregarding any suggestions considered unacceptable. Revised manuscripts should be returned in duplicate to the editor. A revised manuscript should be received by the Editorial Office not later than 5 weeks (in case of minor revision) or 10 weeks (in case of extensive revision) after the editorial decision was sent to the author(s); otherwise it will be processed as a new manuscript. Handwritten additions or corrections will not be accepted. Only complete retyping of the pages affected by revision is acceptable.

GENERAL INSTRUCTIONS

For extensive 'Notice to Authors' see Vol. 133, No. 1, p. 1.

The original and 2 copies, complete with 3 sets of figures and tables should be sent to:

The Editorial Office of the European Journal of Pharmacology,
P.O. Box 5023, 3502 JA Utrecht, The Netherlands

Manuscripts should be typewritten with double line spacing and with wide margins to the left *and* to the right (not more than 26 lines per page). The pages should be numbered consecutively, the title page being p. 1. Manuscripts should be written in English. The manuscripts will, if necessary, be corrected for English style and language. Such correction will be carried out by a qualified pharmacologist and is final.

1. Rapid communications

(a) Reports on exciting new results within the scope of the Journal can be submitted for publication in the Rapid communications section.
(b) A Rapid communication should not exceed 600 words and should contain no or only one simple table or figure of not more than *7.5 cm = 1 column width*. A figure of more than 1 column width will delay publication by at least 14 days.
(c) A maximum of 5 references may be used (see inside back cover).
(d) The Rapid communication should be typewritten, lines double spaced, with wide margins, without any subheadings and without an abstract. Name, postal address, telephone and telex numbers of author to whom correspondence is to be sent should be mentioned on the title page.
(e) Rapid communications have priority at the Editorial Office and Publishers.
(f) All proofreading will be done by the editorial staff of the Publishers; no proofs will be sent to the author(s).

2. Full length manuscripts

(a) The manuscript of a full length paper or Short communication should be arranged in the following order: title (not exceeding 85 characters including spaces between words), surname of author(s), preceded by one name spelled out in full, name and address of the establishment where the work was done, name, postal address, telephone and telex numbers of author to whom proofs and other correspondence should be sent (all on one page), abstract and index words, Introduction, Materials and methods, Results, Discussion, Acknowledgements, References, figure legends, tables and figures. These sections are to be numbered consecutively: 1. Introduction; 2. Materials and methods; 3. Results; 4. Discussion. Subdivisions of a section should also be numbered within that section: 2.1., 2.2., 2.3. etc.
(b) Abstracts and Keywords: an abstract not exceeding 150 words and stating what was done, what was found, and what was concluded should be typed on a separate sheet. It will appear at the beginning of the article. Below the Abstract, type 3 to 6 index words or short phrases suitable for indexing. These terms will be printed at the end of the abstract. If possible, Keywords should be selected from Index Medicus or Excerpta Medica Index. First category Keywords (e.g. Hyperphagia, G-Strophantidin, Fiber shortening) will all be listed and cross-indexed. Second category Keywords (e.g. Rat, Cold, Metabolites) will only be listed under the index entry for the first category Keywords.
(c) Standard nomenclature should be used throughout; unfamiliar or new terms and arbitrary abbreviations should be defined when first used. Unnecessary abbreviations and symbols are to be avoided. Words at the end of a line should not be divided. Use of hyphens, capital letters, numbers written or spelled out (e.g. 8 or eight) should be consistent throughout the manuscript.
(d) Legends of illustrations and footnotes should be typed on separate sheets, lines double spaced. Footnotes, to be numbered consecutively in superscript throughout the text, should be used as little as possible.
(e) Drugs: generic names should be used. Trade names may be mentioned in parentheses the first time the name of the drug appears in the text. The form of the drug used should be indicated.

3. Short communications should be prepared as described under 2., except for the following:

(a) The average length of a Short communication should be between 1500 and 2000 words, which is about 4 double-spaced typewritten pages with a maximum of 2 illustrations (figures and tables).
(b) An abstract of not more than 75 words should be provided and 3 to 6 index words should be listed immediately below the abstract.
(c) Papers will generally be either accepted or rejected; they may be accepted after modification.
(d) All proofreading will be done by the editorial staff of the Publishers; no proofs will be sent to the author(s).
(e) Short communications should not contain more than 10 references.
(f) Upon acceptance of a short communication a reprint order form will be sent to the author(s).

4. References

References in the text to literature cited should be given by the name of the author(s), followed by the year of publication in parentheses, e.g.: Downie and Larsson (1984) *or* (Hicks et al., 1984; 1985; Seeman et al., 1985; Stoof and Kebabian, 1984). For three or more authors the name of the first author followed by et al. should be used. References should be abbreviated according to *Chemical Abstracts*. References should be listed alphabetically at the end of the paper. Two ore more references to the same first author with the same publication year should have a, b, c etc. suffixed to the year to indicate the alphabetical order of the second or third author, as the case may be. Citations of the literature in the list of references should include the full title of the article referred to. Personal communications and unpublished data should not appear in the list of references.

(continued on page 3 of cover)

EUROPEAN JOURNAL OF PHARMACOLOGY